C12N 2710/24161
Methods of inactivation or attenuation
C12N2710/24161 (Methods of inactivation or attenuation) appears on 60 US grants and 84 published applications in this corpus.
Search patents in C12N- Granted patents
- 60
- Published applications
- 84
- Assignees
- 41
- Inventors
- 156
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 4 |
| 2004 | 3 | 0 |
| 2005 | 1 | 5 |
| 2006 | 2 | 5 |
| 2007 | 0 | 5 |
| 2008 | 0 | 1 |
| 2009 | 2 | 11 |
| 2010 | 3 | 3 |
| 2011 | 5 | 4 |
| 2012 | 6 | 5 |
| 2013 | 0 | 5 |
| 2014 | 5 | 6 |
| 2015 | 3 | 1 |
| 2016 | 2 | 2 |
| 2017 | 1 | 5 |
| 2018 | 3 | 1 |
| 2019 | 2 | 4 |
| 2020 | 4 | 4 |
| 2021 | 3 | 2 |
| 2022 | 2 | 5 |
| 2023 | 1 | 3 |
| 2024 | 1 | 1 |
| 2025 | 0 | 1 |
| 2026 | 2 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Oncolytic vaccinia virus21 Jul 2026US 12,686,856 B2KM Biologics Co., Ltd.
- Oncolytic vaccinia virus26 May 2026US 12,637,663 B2KM Biologics Co., Ltd.
- Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy21 May 2024US 11,986,503 B2Memorial Sloan Kettering Cancer Center
- Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy3 Jan 2023US 11,541,087 B2Memorial Sloan Kettering Cancer Center
- Recombinant vaccinia virus and use thereof27 Sep 2022US 11,452,770 B2Kolon Life Science, Inc.
- Improved vaccinia virus vectors2 Oct 2025US 2025/0302997 A1
- Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines25 Jul 2024US 2024/0245765 A1Poximmunomics LLC
- Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy5 Oct 2023US 2023/0310526 A1Memorial Sloan Kettering Cancer Center
- Oncolytic Vaccinia Virus21 Sep 2023US 2023/0293608 A1Queen Mary University of London
- Treatment of immune depression17 Aug 2023US 2023/0256057 A1Transgene S. A.
Most cited
By later US patents
- Microorganisms for therapy104US 7,588,767 B2Genelux Corporation · 2009
- Microorganisms for therapy98US 7,754,221 B2Genelux Corporation · 2010
- Microorganisms for therapy85US 7,588,771 B2Genelux Corporation · 2009
- Microorganisms for therapy77US 7,662,398 B2Genelux Corporation · 2010
- Microorganisms for therapy58US 8,021,662 B2Genelux Corporation · 2011